In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.
早期帕金森病中,每日皮下注射lixisenatide可在12個月內減少運動障礙的進展。
Ann Intern Med 2024-09-02
Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease.
Exendin-4和linagliptin在帕金森氏病小鼠模型中減輕神經炎症。
Neural Regen Res 2023-05-05
A novel protective modality against rotenone-induced Parkinson's disease: A pre-clinical study with dulaglutide.
一種新的保護方式對抗羅滕酮誘導的帕金森病:dulaglutide 的臨床前研究。
Int Immunopharmacol 2023-06-01
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson's Disease.
Incretin類擬物恢復LUHMES多巴胺樣神經元的ER-粒線體軸並將細胞命運轉向存活:對帕金森氏病的新治療策略的意義。
J Parkinsons Dis 2023-11-21
A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.
一種雙重GLP-1/GIP受體激動劑在A53T小鼠帕金森氏症模型中比利拉谷肽更有效。
Parkinsons Dis 2023-10-05
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
NLY01在早期未治療帕金森氏症中的安全性、耐受性和有效性:一項隨機、雙盲、安慰劑對照試驗。
Lancet Neurol 2024-03-15
Impact of alogliptin on lipopolysaccharide-induced experimental Parkinson's disease: Unrevealing neurochemical and histopathological alterations in rodents.
Alogliptin對脂多醣誘導的實驗性帕金森病的影響:揭示啮齒動物神經化學和組織病理學的變化。
Eur J Pharmacol 2024-05-13
Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.
Lixisenatide在早期帕金森病中的功效、安全性和未來方向:一封通函。
Neurosurg Rev 2024-05-24
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
GLP-1 受體激動劑與 2 型糖尿病患者帕金森病風險:一項基於人群的隊列研究。
Mov Disord 2024-08-27